Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study.
Cabozantinib
Delphi study
Everolimus
Immunotherapy
Nivolumab
Renal cell carcinoma
TKI
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
19 Feb 2019
19 Feb 2019
Historique:
received:
20
11
2018
accepted:
28
01
2019
entrez:
21
2
2019
pubmed:
21
2
2019
medline:
14
6
2019
Statut:
epublish
Résumé
The introduction of targeted therapy for the treatment of advanced renal cell carcinoma (RCC) has improved the outcome of these patients in the last decade. However, many patients still relapse. The aim of this consensus study was to establish common recommendations about the best treatment options in patients with RCC. A two-round Delphi methodology was used. A total of 25 statements were submitted to a panel of 30 specialists. If consensus was not obtained in the first round a second and last round was performed. Agreement was achieved for 19 of the proposed 25 statements (76%). When making a decision about the treatment option, considering the efficiency and response rate to previous treatment, drug's toxicity and the patients' clinical features are very relevant.
Identifiants
pubmed: 30783817
doi: 10.1007/s12032-019-1251-7
pii: 10.1007/s12032-019-1251-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Références
Cancer Res. 2006 Apr 1;66(7):3381-5
pubmed: 16585157
N Engl J Med. 2007 Jan 11;356(2):125-34
pubmed: 17215530
Oncologist. 2007 Jul;12(7):864-72
pubmed: 17673617
Lancet. 2008 Aug 9;372(9637):449-56
pubmed: 18653228
Nat Rev Cancer. 2008 Nov;8(11):865-73
pubmed: 18923434
Therapy. 2011 Jul;8(4):359-367
pubmed: 21894244
Mol Cancer Ther. 2011 Dec;10(12):2298-308
pubmed: 21926191
Lancet. 2011 Dec 3;378(9807):1931-9
pubmed: 22056247
Expert Opin Biol Ther. 2013 Jun;13(6):847-61
pubmed: 23421934
Br J Cancer. 2013 Apr 30;108(8):1571-8
pubmed: 23579211
J Clin Epidemiol. 2014 Apr;67(4):401-9
pubmed: 24581294
Recent Results Cancer Res. 2014;201:373-92
pubmed: 24756805
Br J Cancer. 2014 Jun 10;110(12):2821-8
pubmed: 24823696
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
Lancet Oncol. 2015 Nov;16(15):1473-1482
pubmed: 26482279
Lancet Oncol. 2016 Jan;17(1):e4-5
pubmed: 26758760
Lancet Oncol. 2016 Jul;17(7):917-927
pubmed: 27279544
Nat Rev Urol. 2016 Jul;13(7):420-31
pubmed: 27324121
Mod Pathol. 2016 Nov;29(11):1347-1357
pubmed: 27469331
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
N Engl J Med. 2017 Jan 26;376(4):354-366
pubmed: 28121507
J Clin Oncol. 2017 Feb 20;35(6):591-597
pubmed: 28199818
Eur Urol. 2017 Dec;72(6):962-971
pubmed: 28262413
CA Cancer J Clin. 2017 Nov;67(6):507-524
pubmed: 28961310
Crit Rev Oncol Hematol. 2017 Nov;119:23-28
pubmed: 29065981
Oncology (Williston Park). 2017 Dec 15;31(12):919-26, 928-30
pubmed: 29297173
Indian J Med Paediatr Oncol. 2017 Oct-Dec;38(4):520-525
pubmed: 29333023
Oncologist. 2018 May;23(5):540-555
pubmed: 29487224
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Ann Oncol. 2018 Nov 1;29(11):2208-2213
pubmed: 30215677
BMJ. 1995 Aug 5;311(7001):376-80
pubmed: 7640549